Abstract:<h3>Purpose/Objective(s)</h3> To retrospectively investigate the efficacy and prognostic factors of multiple/all lesions stereotactic ablative radiotherapy (SABR) for oligometastatic renal carcinoma (RCC). <h3>Materials/Methods</h3> The present study retrospectively reviewed thirty-five patients with oligometastatic RCC (1-5 metastases) who received stereotactic ablative radiotherapy (SABR) between April 2015 and December 2020. All patients were treated with SABR (6-10Gy/f, 5 or 10f) or partial-SABR boost to the lesions (40-60Gy/20-25f with tumor center boosted with 6-8Gy/f, 3-5f) for bulky tumors or tumors adjacent to critical organs. 31 patients underwent systematic therapy. Daily CBCT image guidance was used for each patient. Thirty-one patients underwent targeted therapy or targeted plus immunotherapy. <h3>Results</h3> 35 patients with 8 primary lesions and 92 metastatic lesions were included in this study. The median follow-up time was 17.0 months (range 6.1-75.4 months). The average age of all patients was 63 years. Clear cell renal cell carcinoma accounted for 77.1% of all RCC cases. Four patients (11.4%) had sarcomatoid differentiation. 78.5% of the patients had an intermediate or poor IMDC risk. Surgery on primary or metastatic sites was previously performed in 85.7% patients. The median time interval from first distant metastasis radiation therapy (DM-RT) was 7.2 months (range 0 to 50.2 months). Of the patients, 19 were treated for all primary and/or metastatic lesions. Forty percent of the patients received RT before tyrosine kinase inhibitor (TKI) failure. Of the 48 irradiated lesions, 15 received SABR, and 33 received partial-SABR. The local control rate (LRFS), progression-free survival rate (PFS) and overall survival rate (OS) of the whole group at 1 and 3 years were 78% and 78% and 41.8% and 27.9% and 78.3% and 48.2%, respectively. Univariate analysis showed that OS benefit were found in patients who received radiation before tyrosine kinase inhibitor (TKI) failure (p = 0.006) and a short time interval (<6 months) to radiotherapy (p = 0.046). Similar results were also found in PFS in patients who received radiation before TKI failure (p = 0.049) or within 8 months (p = 0.047). There were certain differences in PFS (P = 0.033) between patients receiving radiotherapy to all lesion and those to selected tumors. In multivariate analysis, OS benefits were found in patients who received SABR before TKI failure (p = 0.028). There were certain differences in PFS (P =0.033) between patients receiving radiotherapy to all lesion and those to selected tumors. In multivariate analysis, OS benefits were found in patients who received radiotherapy before TKI failure (p = 0.028), but there was no significant difference in relation to other characters due to the small sample size. <h3>Conclusion</h3> Early use of SABR and all sites irradiation may improve survival. Partial-SABR for bulky lesions close to critical organs could be safely and effectively applied under certain circumstances.

Is local ablative stereotactic radiation therapy a valuable rescue strategy for time on drug in patients enrolled in phase I trials?

The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)

A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR)

Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial

Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)

Effectiveness of radiotherapy in delaying treatment changes in primary or secondary immunorefractory oligoprogressive patients: preliminary results from a single-center study

Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study

Isolated Progression of Metastatic Lung Cancer: Clinical Outcomes Associated with Definitive Radiotherapy.

Outcomes of Multiple/All lesions Stereotactic Ablative Radiation Therapy (SABR) for Oligo-Metastatic Renal Cancer

Stereotactic Ablative Radiotherapy for Oligoprogressive Cancers: Results of the Randomized Phase II STOP Trial

Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients

Efficacy of Stereotactic Body Radiotherapy for Oligoprogression on PD-1 Axis Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).

Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions

Upfront versus Delayed Systemic Therapy in Patients with Oligometastatic Cancer Treated with Stereotactic Ablative Radiotherapy on the Phase II SABR-5 Trial

Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer

(ARTO trial-NCT03449719): Role of local treatment after progression in patients with castrate-resistant prostate cancer undergoing first-line abiraterone treatment.